Cyramza Solution For Injection 10Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Cyramza: Solution for injection (10mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

RAMUCIRUMAB (ra mue SIR ue mab) is a chemotherapy drug. It is used to treat stomach cancer or lung cancer. This drug targets a specific protein receptor on cancer cells and stops the cancer cells from growing.

In-Depth Information
Select a Medication

Cyramza 500mg/50mL Solution for Injection

NDC: 000027678
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), Gastric Cancer

Storage Information
Refrigerate (between 36 and 46 degrees F)
Protect from light
Store in carton
Discard product if it contains particulate matter, is cloudy, or discolored
Do not freeze
Cyramza 500mg/50mL Solution for Injection

Reported Side Effects for Cyramza 500mg/50mL Solution for Injection

Low Albumin In Blood Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Infection Incidence:
<6.0%*
Severity: MILD
Onset: DELAYED
Fluid Retention Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Antibody Formation Incidence:
<3.3%*
Severity: MODERATE
Onset: DELAYED
Secretion Of Tears Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Brain Deterioration Incidence:
<0.1%*
Severity: SEVERE
Onset: DELAYED
Hand And Foot Syndrome Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Decreased Appetite Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Nose Bleed Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Underactive Thyroid Incidence:
<2.6%*
Severity: MODERATE
Onset: DELAYED
Infusion-related Reactions Incidence:
0.4-16.0%*
Severity: MODERATE
Onset: RAPID
Nephrotic Syndrome Incidence:
0.6%*
Severity: SEVERE
Onset: DELAYED
Hole In Intestines Incidence:
0.7-1.7%*
Severity: SEVERE
Onset: DELAYED
Bleeding Incidence:
1.0-4.3%*
Severity: SEVERE
Onset: EARLY
Protein In The Urine Incidence:
1.0-3.0%*
Severity: SEVERE
Onset: DELAYED
Mouth Ulcers Incidence:
1.0-7.0%*
Severity: SEVERE
Onset: DELAYED
Loose Stools Incidence:
1.0-4.0%*
Severity: SEVERE
Onset: EARLY
Blood Clot Incidence:
1.7%*
Severity: SEVERE
Onset: DELAYED
Low Platelet Count Incidence:
2.0-3.0%*
Severity: SEVERE
Onset: DELAYED
Intestinal Bleeding Incidence:
2.0-4.0%*
Severity: SEVERE
Onset: DELAYED
Intestinal Blockage Incidence:
2.1%*
Severity: SEVERE
Onset: DELAYED
Low Blood Sodium Levels Incidence:
3.0%*
Severity: SEVERE
Onset: DELAYED
Skin Rash Incidence:
4.2%*
Severity: MILD
Onset: EARLY
High Blood Pressure Incidence:
6.0-15.0%*
Severity: SEVERE
Onset: EARLY
Headache Incidence:
9.0%*
Severity: MILD
Onset: EARLY
Tired Incidence:
12.0-14.0%*
Severity: SEVERE
Onset: EARLY
Weakness Incidence:
12.0-14.0%*
Severity: SEVERE
Onset: DELAYED
Low White Blood Cells Incidence:
38.0-49.0%*
Severity: SEVERE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Cyramza

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5